Wednesday, February 26, 2020 9:07:58 AM
ProMIS Neurosciences initiates Natural History Study of Blood-Based Biomarkers in Alzheimer’s Disease
By Promis Neuro Admin on Feb 26, 2020 07:30 am
Biomarkers offer opportunity to make go/no-go decisions for investigational therapies as early as Phase 1
TORONTO, Ontario and CAMBRIDGE, Mass. — February 26, 2020 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), with Toronto Memory Program, Canada’s largest and most experienced memory clinic and site for drug treatment trials in Alzheimer’s disease (AD) has initiated a pilot longitudinal study to assess the level of blood-based biomarkers in early AD with the support of Parexel, one of the world’s leading global clinical research organizations (CROs). ProMIS will leverage Parexel’s significant data management and central nervous system (CNS) expertise for the study, which it will use as the historical control arm for its anticipated Phase 1 study of PMN310, a novel antibody that selectively targets the toxic oligomeric species of amyloid beta, a root cause of AD. The dataset will help ProMIS detect a treatment signal as early as Phase 1, potentially allowing for rapid proof-of-concept at a fraction of the expense associated with traditional clinical trials. The dataset will be made available as a communal resource for Alzheimer’s researchers.
“Alzheimer’s patients and their families have endured far too many late-stage therapy failures,” said Sharon Cohen, MD, FRCPC, Medical Director of Toronto Memory Program and Principal Investigator of the study. “A new generation of blood-based biomarkers offers researchers the opportunity to measure treatment success much earlier than with traditional methods. As both a clinician and researcher, being able to detect a treatment signal in Phase 1 allows me to proceed with confidence knowing I’m focused on a validated therapy candidate with credible potential for success with my patients.”
Parexel will support ProMIS on the assimilation and management of this large data set, aimed at helping the industry derive important insights to drive the development of future therapies.
“As a truly patient-focused CRO, it’s an incredibly exciting time to be involved in Alzheimer’s disease therapy research as we await FDA’s decision regarding the first disease-modifying therapy, aducanumab,” shared Sy Pretorius, MD, Executive Vice President and Chief Medical and Scientific Officer, Parexel. “Harnessing the power of biomarker data holds great potential in helping to reach the next generation of innovation with the ultimate goal of bringing more therapies to market for Alzheimer’s patients, their caregivers and their families.”
“The U.S. Food and Drug Administration (FDA) has indicated it will accelerate approval of potential Alzheimer’s disease therapies if researchers can demonstrate meaningful biomarker changes,” said James Kupiec, MD, Chief Medical Officer for ProMIS Neurosciences, the study sponsor. “The Alzheimer’s research community has desperately needed a reliable, reproducible way to measure a drug’s effectiveness earlier than Phase 2 or 3 at which time so much money, patient hardship and time have been expended. The expected dataset could help facilitate the detection of a meaningful signal as early as Phase 1. This is really critical as it may enable us to advance only the best candidates with the highest potential for success. We look forward to using these data to advance PMN310 quickly. In addition, we will offer the biomarker dataset to the research community to help advance additional therapies.”
Several highly sensitive biomarkers are currently in development that could measure neuronal injury more accurately and/or more conveniently than current standards. Significantly, this new generation of blood-based biomarkers may afford drug developers a convenient means to measure the effectiveness of potential disease-modifying therapies as early as Phase 1, sparing patients, investors and researchers the time, expense and anguish associated with late-stage clinical trial failures.
Toronto Memory Program will lead this non-interventional natural history study which will measure the concentrations of neurofilament light chain (NfL) and other blood-based biomarkers on a monthly basis for a period of six months in AD patients with early stage disease. Designed to support multiple centers and up to 100 patients, the study will evaluate the plasma concentration of these biomarkers over the course of the study as well as visit-to-visit variability. The monthly data collection mirrors the design of a Phase 1 interventional trial where monthly blood draws to evaluate plasma biomarker levels coincide with monthly treatments/infusions.
The depth of the biomarker data from the natural history study will offer a powerful historical reference group with multiple monthly data points per patient.
Recent PMN News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/24/2024 10:56:35 PM
- ProMIS Neurosciences to Showcase PMN310’s Ability to Target Toxic Oligomers and Distinguish from Other Amyloid-Beta Oligomers in Preclinical Studies at the 4th International Conference on Cognitive & Behavioral Neurosciences • GlobeNewswire Inc. • 09/12/2024 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/09/2024 08:10:10 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 09/09/2024 08:05:20 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/09/2024 04:15:07 AM
- ProMIS Neurosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2024 11:00:00 AM
- ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology • GlobeNewswire Inc. • 08/06/2024 11:00:00 AM
- ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024 • GlobeNewswire Inc. • 08/01/2024 11:00:00 AM
- ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference • GlobeNewswire Inc. • 07/30/2024 12:30:00 PM
- ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial • GlobeNewswire Inc. • 07/26/2024 12:35:00 PM
- ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing • GlobeNewswire Inc. • 07/26/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:15:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:25:22 PM
- ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights • GlobeNewswire Inc. • 05/14/2024 08:01:00 PM
- ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies • GlobeNewswire Inc. • 04/30/2024 11:00:00 AM
- ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS • GlobeNewswire Inc. • 04/09/2024 11:00:00 AM
- ProMIS Neurosciences to Present in Upcoming Investor Conferences in April • GlobeNewswire Inc. • 04/04/2024 11:00:00 AM
- ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights • GlobeNewswire Inc. • 04/01/2024 08:15:00 PM
- ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio • GlobeNewswire Inc. • 03/11/2024 11:00:00 AM
- ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine • GlobeNewswire Inc. • 01/22/2024 12:00:00 PM
- ProMIS Neurosciences Issues Letter to Shareholders • GlobeNewswire Inc. • 01/08/2024 12:00:00 PM
- ProMIS Neurosciences, Inc. Announces Leadership Transition • GlobeNewswire Inc. • 01/03/2024 12:00:00 PM
- ProMIS Neurosciences Announces Publication on Novel Target for ALS • GlobeNewswire Inc. • 12/20/2023 12:00:00 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM